Cello Group plc  

(Public, LON:CLL)   Watch this stock  
Find more results for Paul L. Chello
+0.44 (0.48%)
Jan 29 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 90.00 - 91.44
52 week 81.00 - 100.00
Open 91.00
Vol / Avg. 27,009.00/73,778.00
Mkt cap 77.86M*
P/E 16.14
Div/yield 0.80/2.64*
EPS 0.06*
Shares 84.85M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 3.01% 2.27%
Operating margin 4.65% 3.77%
EBITD margin - 6.74%
Return on average assets 3.94% 3.19%
Return on average equity 6.75% 5.43%
Employees 900 -
CDP Score - -


11-13 Charterhouse Buildings
United Kingdom - Map
+44-20-78128460 (Phone)
+44-20-72535376 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Cello Group plc is a United Kingdom-based holding company. The Company, along with its subsidiaries, is engaged in the market research, consulting and direct marketing services. The Company operates in two segments: Cello Health and Cello Signal. The Cello Health division provides market research, consulting and communications services principally to the Company�s pharmaceutical and healthcare clients. The Cello Signal division provides market research and direct communications services principally to the Company�s consumer facing clients. The Company�s subsidiaries include 2CV Limited, Cello Group Inc, Cello Business Sciences Limited, Chiaros Holdings Limited, Fenix Media Limited, Insight Medical Research Limited, Leapfrog Research and Planning Limited, MedErgy Europe Limited and Worldwide Promedica Inc.

Officers and directors

Mark Scott Chief Executive, Executive Director
Mark Bentley Group Finance Director, Company Secretary, Executive Director
Stephen Highley Group Corporate Development Director, Director
Allan Rich Independent Non-Executive Chairman of the Board
William Nigel David Independent Non-Executive Director
Paul Hamilton Senior Independent Non Executive Director